Loading...
OTCM
NSTGQ
Market cap3mUSD
Jun 25, Last price  
0.07USD
Name

NanoString Technologies Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.35%
Rev. gr., 5y
2.06%
Revenues
127m
-12.28%
34,422,00011,730,00017,800,00022,973,00031,403,00047,593,00062,667,00086,489,000114,905,000106,732,000125,568,000117,316,000145,085,000127,262,000
Net income
-160m
L+38.43%
-44,114,000-12,768,000-10,932,000-17,708,000-29,281,000-50,038,000-45,581,000-47,089,000-43,562,000-77,400,000-40,696,000-110,078,000-115,254,000-159,543,000
CFO
-129m
L+42.03%
-10,965,000-10,692,000-14,808,000-31,346,000-38,061,000-43,362,000-6,079,000-51,657,000-54,065,000-89,421,000-81,662,000-90,549,000-128,606,000

Profile

NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
URL
https://www.nanostring.com/
IPO date
Jun 26, 2013
Employees
703
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
127,262
-12.28%
Cost of revenue
279,445
Unusual Expense (Income)
NOPBT
(152,183)
NOPBT Margin
Operating Taxes
317
Tax Rate
NOPAT
(152,500)
Net income
(159,543)
38.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,605
BB yield
-0.70%
Debt
Debt current
5,518
Long-term debt
268,864
Deferred revenue
3,754
Other long-term liabilities
(226,622)
Net debt
77,850
Cash flow
Cash from operating activities
(128,606)
CAPEX
(23,066)
Cash from investing activities
132,497
Cash from financing activities
(2,556)
FCF
(172,806)
Balance
Cash
196,532
Long term investments
Excess cash
190,169
Stockholders' equity
(809,880)
Invested Capital
883,328
ROIC
ROCE
EV
Common stock shares outstanding
46,406
Price
7.97
-81.13%
Market cap
369,856
-80.67%
EV
447,706
EBITDA
(144,067)
EV/EBITDA
Interest
7,535
Interest/NOPBT